Author:
Dafni U.,Soo R.A.,Peters S.,Tsourti Z.,Zygoura P.,Vervita K.,Han J.-Y.,De Castro J.,Coate L.,Früh M.,Hashemi S.M.S.,Nadal E.,Carcereny E.,Sala M.A.,Bernabé R.,Provencio M.,Cuffe S.,Roschitzki-Voser H.,Ruepp B.,Rosell R.,Stahel R.A.
Reference31 articles.
1. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2016
2. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer;Hung;Oncol Lett,2016
3. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis;Viloria-Petit;Cancer Res,2001
4. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial;Nakagawa;Lancet Oncol,2019
5. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial;Rosell;Lancet Respir Med,2017
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献